Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 21;64(5):e00027-20.
doi: 10.1128/AAC.00027-20. Print 2020 Apr 21.

Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment

Ernane Souza  1 , Ryan L Crass  1 , Jeremy Felton  2 , Kengo Hanaya  3 , Manjunath P Pai  4
Affiliations

Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment

Ernane Souza et al. Antimicrob Agents Chemother. .

Abstract

In patients with renal impairment (n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

Keywords: dialysis; myelosuppression; oxazolidinones; pharmacodynamics; toxicology.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Comparison between parent linezolid (LZD) and metabolite concentrations. (A) Metabolite-to-parent concentration ratios stratified by renal impairment. (B) Linear regression between LZD and metabolite concentrations. Linear correlation between the concentrations of LZD and PNU-142300 was 0.98 + 0.44 × LZD (r2 = 0.26). Linear correlation between the concentrations of LZD and PNU-142586 was 9.74 + 0.57 × LZD (r2 = 0.06).
See this image and copyright information in PMC

References

    1. Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H. 2017. Linezolid: a promising option in the treatment of Gram-positives. J Antimicrob Chemother 72:354–364. doi:10.1093/jac/dkw450. - DOI - PubMed
    1. Lee EY, Caffrey AR. 2018. Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother 62:1–4. doi:10.1128/AAC.01453-17. - DOI - PMC - PubMed
    1. French G. 2003. Safety and tolerability of linezolid. J Antimicrob Chemother 51(Suppl 2):ii45–ii53. doi:10.1093/jac/dkg253. - DOI - PubMed
    1. Cattaneo D, Alffenaar JW, Neely M. 2016. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Expert Opin Drug Metab Toxicol 12:533–544. doi:10.1517/17425255.2016.1166204. - DOI - PubMed
    1. Crass RL, Cojutti PG, Pai MP, Pea F. 2019. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob Agents Chemother 63:1–10. doi:10.1128/AAC.00605-19. - DOI - PMC - PubMed

Publication types

MeSH terms